| --- | --- | |---------------------------------------------|-------| | | | | | | | Investor Presentation April 2019 | | | oncolyticsbiotech.com Nasdaq ONCY TSX | | Forward Looking Statements This presentation contains certain forward looking statements relating to the company's business prospects and the development and commercialization of pelareorep, a first-in-class systemically administered immuno-oncology agent for solid tumors and heme malignancies. These statements are based on management's current ...